Nuwellis, Inc. To Announce First Quarter 2026 Financial Results on May 12, 2026
Nuwellis (Nasdaq: NUWE) will report first-quarter 2026 financial results for the period ended March 31, 2026, premarket on Tuesday, May 12, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nuwellis (Nasdaq: NUWE) will report first-quarter 2026 financial results for the period ended March 31, 2026, premarket on Tuesday, May 12, 2026. A conference call and webcast will follow at 9:00 AM ET on May 12, 2026 to discuss results and provide a company update.
Investors can access the live webcast on the company Investors page (https://ir.nuwellis.com) or listen by phone at 1-800-274-8461 (U.S.) or 1-203-518-9814 (international) using conference ID NUWEQ1. An audio archive will be available after the call.
Details
News Market Reaction – NUWE
On May 5, the day this news came out, NUWE closed 0.89% below the previous close.
Data tracked by StockTitan Argus for the May 5 session.
Key Figures
- Registered shares
- 4,279,325 shares
- Resale registration of warrant shares under S-3 shelf
- Potential warrant proceeds
- $28 million
- Maximum cash if all registered warrants exercised
- Shares outstanding
- 1,873,892 shares
- Common stock outstanding as of Jan 31, 2026
- Record date shares
- 2,635,718 shares
- Common shares outstanding on Mar 24, 2026 proxy record date
- Options per director
- 6,744 options
- Nonstatutory stock option grants to several directors
- Option exercise price
- $1.16 per share
- Exercise price for April 27, 2036-expiring director options
- Settlement payment
- $204,000
- Contract dispute settlement with E.F. Hutton & Co.
- Meeting representation
- 1,078,020 shares
- Shares represented at 2026 annual stockholder meeting
Previous Earnings date Reports
-
Announced Q4 and full-year 2025 results date and conference call details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
cardiorenal medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, May 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will report its financial results for the first quarter ended March 31, 2026 premarket on Tuesday, May 12, 2026.
The Company will subsequently host a conference call and webcast at 9:00 AM ET on May 12, 2026 to discuss its financial results and provide an update on the Company's performance.
To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com or access here.
Alternatively, you may listen to the live conference call by dialing 1-800-274-8461 (U.S.) or 1-203-518-9814 (international) and using the conference ID: NUWEQ1. An audio archive of the webcast will be available following the call on the Investors page.
For more information, visit www.nuwellis.com.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
ir@nuwellis.com
Media Contact:
CORE PR
media@nuwellis.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.